What if there was
a vaccine for Alzheimer’s?
Today, Alzheimer’s disease affects almost every family, in every society. More than 30 million individuals are diagnosed with Alzheimer’s. Alzinova is the pioneer in the development of a vaccine that has the potential to change that.
80% of dementia patients suffer from Alzheimer’s disease
Dementia primarily afflicts older people, but it is not part of normal ageing. Alzheimer’s is the only top killer that cannot be prevented, cured, or even slowed down and it imposes a high cost on society. Addressing the high unmet medical needs in Alzheimer’s disease is therefore a major priority for both publicly funded scientific research and the healthcare industry. Learn more
Video Explainer
About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company pioneering the development of an active immunotherapy against Alzheimer’s disease. The vaccine is in clinical development and tested in patients. The company’s shares (ALZ) are listed on Nasdaq First North Growth Market, Stockholm.
How big is the problem?
Learn more about Alzheimer’s disease and how Alzinova is addressing the high unmet medical need in this indication. Read more
What is our solution?
Learn more about how Alzinova is using it’s unique proprietary ”AβCC Peptide™ Technology” to develop disease-modifying treatments against Alzheimer’s disease. Read more
Latest news
- 2024-04-23 Our CSO, Anders Sandberg, comments on new assay data in BioStock interview
- 2024-04-11 BioStock interview